Walleye Capital
SCPH

Walleye Capital’s scPharmaceuticals SCPH Stock Holding History

Walleye Capital’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,284
Closed -$43K – 5061
2025
Q2 		$43K Buy
+11,284
New +$35K ﹤0.01% 4083
2024
Q4 		– Sell
-475,555
Closed -$2.17M – 5476
2024
Q3 		$2.17M Buy
475,555
+101,148
+27% +$489K ﹤0.01% 1867
2024
Q2 		$1.63M Sell
374,407
-181,779
-33% -$799K ﹤0.01% 2312
2024
Q1 		$2.79M Sell
556,186
-282,694
-34% -$1.58M 0.01% 1745
2023
Q4 		$5.26M Buy
838,880
+412,360
+97% +$2.36M 0.01% 1077
2023
Q3 		$3.04M Sell
426,520
-133,140
-24% -$1.05M 0.01% 1401
2023
Q2 		$5.7M Buy
+559,660
New +$5.84M 0.02% 654
2020
Q3 		– Sell
-20,943
Closed -$154K – 952
2020
Q2 		$154K Buy
+20,943
New +$184K 0.03% 467

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Walleye Capital's SCPH Position: Q3 2025 in Review

Walleye Capital sold out of scPharmaceuticals (SCPH) in Q3 2025, closing a stake of 11,284 shares — an estimated $43K sold.

Walleye Capital first reported a position in SCPH in Q2 2020 and held it in 8 quarters. The position peaked at $5.7M in Q2 2023. 110 funds tracked by Wall St. Rank hold SCPH as of Q3 2025.

  • Walleye Capital reported no remaining scPharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Walleye Capital sold 11,284 scPharmaceuticals shares in Q3 2025, an estimated $43K.
  • Walleye Capital first reported a position in scPharmaceuticals in Q2 2020 and held it in 8 quarters.
  • Walleye Capital's scPharmaceuticals position peaked at $5.7M in Q2 2023.
  • 110 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2025.

Based on Walleye Capital's 13F filing for Q3 2025, filed 14 Nov 2025.